COMPANY PROFILE

Paradromics

Explore full profile

Developing high-volume bidirectional data streaming capabilities between brains and computers

Austin, United StatesFounded 2015Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2023

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Paradromics

Paradromics is a pioneering company in the neurotechnology sector, focusing on developing advanced brain-computer interfaces (BCIs). These interfaces are designed to collect and interpret vast amounts of neural data to address complex neurological and brain-related medical challenges. The company's flagship product, the Connexus Direct Data Interface (DDI), is a fully implantable device that captures an unprecedented number of individual neural signals. This technology has the potential to revolutionize treatments for a variety of neurological disorders by providing new therapeutic and diagnostic applications.

Read full description

Paradromics primarily serves medical institutions, research organizations, and healthcare providers who are looking to advance their capabilities in treating neurological conditions. The company operates in the medical technology market, specifically within the niche of neurotechnology. This market is characterized by rapid innovation and significant potential for growth, driven by increasing demand for advanced medical solutions.

The business model of Paradromics revolves around the development, manufacturing, and sale of its neurotechnology devices. The company generates revenue through the sale of its Connexus DDI system and related services, including installation, maintenance, and data analysis support. By offering a cutting-edge solution that goes beyond traditional medical devices, Paradromics positions itself as a leader in the neurotech field.

In summary, Paradromics is at the forefront of neurotechnology, leveraging advanced brain data to create innovative solutions for neurological disorders. The company serves a specialized market with high growth potential and generates revenue through the sale and support of its groundbreaking BCI systems.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Austin, United States
Employees: 112
Open positions: 8
Dealroom signal: 89.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Streaming, Biotechnology, Neurology, Spinout, Neural Networks, Brain Computer Interfaces, NIF defense security and resilience
Technology: Big Data, Deep Tech, IoT InternetOfThings
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Paradromics.

See all news

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Feb 2025	$0	—	NEOM Investment Fund (NIF)	↗
SERIES AOther financing	Nov 2023	$17M	$165M	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Paradromics website traffic

Latest recorded traffic for Paradromics is 17K monthly website visits, up 21.4% over the last three months. Paradromics's team grew 17.9% over the past year.

Latest monthly visits17K 3-month web change+21.4% 1-year team growth+17.9%

Monthly website visitsJun 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

People Operations CoordinatorAustin, Texas, United States · Human Resources · Feb 12, 2026 Quality Engineer - SaMD/SiMDAustin, Texas, United States · Other · Jan 17, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MIMindMazeDigital neuro-therapeutics for brain health and recovery	Lausanne, Switzerland	Acquired	89	$338M	$1.5B
MLMerge LabsDeveloping non-invasive brain-computer interface technology to enable direct communication between the human brain and computers	Palo Alto, United States	Operational
MIMintNeuroLow-power semiconductor chips for minimally-invasive neural implants.	London, United Kingdom	Operational
ININBRAIN NeuroelectronicsDeveloping high density and high resolution graphene intelligent Brain Computer Interface (BCI) Therapeutics for central and peripheral modulation	Barcelona, Spain	Operational
RNRestorative NeurotechnologiesProducing wearable medical device in order to enhance the strength of the rehabilitation for cognitive disease or enhance sport performance	Palermo, Italy	Operational
NENeuroelectricsDeveloping a unique platform to treat brain dysfunction with cloud-based, personalized neuromodulation	Barcelona, Spain	Operational
ANAleva NeurotherapeuticsPioneered directional deep brain stimulation DBS in Neuromodulation treatment of Parkinson's disease and essential tremor	Lausanne, Switzerland	Operational
NENeuroVLCCreates lightweight wireless neural recording systems for high-frequency electrophysiological activity observation	Glasgow, United Kingdom	Operational